Chile
PhageLab is a pioneering biotech firm dedicated to developing custom antibacterial solutions tailored to global bacterial challenges. Founded in 2010, the company leverages a robust AI-powered protocol to diagnose and eliminate specific bacterial pathogens effectively, ensuring farm health globally. With more than 14 years of experience, PhageLab partners extensively with poultry and livestock producers, providing fast and precise diagnostics.
Headquartered in Chile, PhageLab stands on the cutting edge of biotechnology and is committed to the One Health principle. With a prominent bacteriophage repository and exceptional data-gathering capabilities, the company leads the intersection of science and technology. Recently, PhageLab secured a $11.00M Series A investment on January 23, 2024, backed by notable investors including Collaborative Fund, WaterLemon Ventures, Nazca Ventures, and Kevin Efrusy. The company's vision is succinctly captured in its slogan: "Science works and we can prove it."
